Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)

European Journal of Cancer

Volumn 64, Issue , 2016, Pages 12-21

  Von Minckwitz, G ^a   Rezai, M ^b   Tesch, H ^c   Huober, J ^d   Gerber, B ^e   Zahm, D M ^f   Hilfrich, J ^g   Costa, S D ^h   Dubsky, P ⁱ   Blohmer, J U ^j   Denkert, C ^j   Hanusch, C ^k   Jackisch, C ^l   Kummel S ^m   Fasching, P A ⁿ   Schneeweiss, A ^o   Paepke, S ^p   Untch, M ^q   Burchardi, N ^a   Mehta, K ^a   Loibl, S ^a   more..

^a C/o GBG Forschungs GmbH ^*  (Germany)

^b Breast Center Düsseldorf Luisenkrankenhaus   (Germany)

^c Onkologische Gemeinschaftspraxis   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^f SRH Wald Klinikum Gera   (Germany)

^g Eilenriede Clinic   (Germany)

^h UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k Frauenklinik Rotkreuzklinikum   (Germany)

^l Klinikum Offenbach   (Germany)

^m KLINIKEN ESSEN MITTE   (Germany)

ⁿ UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^o C o Institut für Medizinische Biometrie und Informatik   (Germany)

^p TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^q HELIOS KLINIKUM BERLIN BUCH   (Germany)

more..

Author keywords

Adjuvant treatment; Early breast cancer; Postneoadjuvant; Zoledronate

Indexed keywords

ANTHRACYCLINE; TAXANE DERIVATIVE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; ALOPECIA; ARTHRALGIA; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; GENERAL CONDITION DETERIORATION; HEADACHE; HOT FLUSH; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; ADJUVANT CHEMOTHERAPY; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; SECONDARY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; NEOPLASM, RESIDUAL;

EID: 84975061726     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.05.015     Document Type: Article

References (19)

1. M. Kaufmann, G. von Minckwitz, E.P. Mamounas, and et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer Ann Surg Oncol 19 2012 1508 1516
2. G. von Minckwitz, M. Untch, J.U. Blohmer, and et al. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 30 2012 1796 1804
3. P. Rastogi, S.J. Anderson, H.D. Bear, and et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 2008 778 785
4. T. Onishi, N. Hayashi, R.L. Theriault, and et al. Future directions of bone-targeted therapy for metastatic breast cancer Nat Rev Clin Oncol 7 2010 641 651
5. I.J. Diel, E.F. Solomayer, S.D. Costa, and et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment N Engl J Med 339 1998 357 363
6. R. Coleman, R. de Boer, H. Eidtmann, and et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results Ann Oncol 24 2013 398 405
7. H.M. Kuerer, L.A. Newman, T.L. Smith, and et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 1999 460 469
8. C.A. Hudis, W.E. Barlow, J.P. Costantino, and et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system J Clin Oncol 25 2007 2127 2132
9. M.K. Parmar, G.O. Griffiths, D.J. Spiegelhalter, and et al. Monitoring of large randomised clinical trials: a new approach with Bayesian methods Lancet 358 2001 375 381
10. R. Coleman, D. Cameron, D. Dodwell, and et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial Lancet Oncol 15 2014 997 1006
11. D. Mauri, A. Valachis, N.P. Polyzos, and et al. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials J Natl Compr Canc Netw 8 2010 279 286
12. R.E. Coleman, H. Marshall, D. Cameron, and et al. Breast-cancer adjuvant therapy with zoledronic acid N Engl J Med 365 2011 1396 1405
13. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials Lancet 386 2015 1353 1361
14. M. Gnant Zoledronic acid in breast cancer: latest findings and interpretations Ther Adv Med Oncol 3 2011 293 301
15. G. von Minckwitz, V. Möbus, A. Schneeweiss, and et al. German Adjuvant Intergroup Node-Positive Study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer J Clin Oncol 31 2013 3531 3539
16. E.A. Mittendorf, J.S. Jeruss, S.L. Tucker, and et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy J Clin Oncol 29 2011 1956 1962
17. W.F. Symmans, C. Wei, R. Gould, and et al. Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy Cancer Res 73 2013 S6-02
18. E.G. Geyer, S. Loibl, E.P. Mamounas, and et al. A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE) Cancer Res 73 2013 OT1-1-06
19. G. von Minckwitz, H. Bear, H. Bonnefoi, and et al. PENELOPE: phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13) Cancer Res 73 2013 OT2-6-11